Clinical Trial Update: The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease [Phase 1, Phase 2]

View source ↗

Summary

This document reports a Phase 1/2 clinical trial evaluating intravenous EXG110 in patients with Fabry disease, conducted by Guangzhou Jiayin Biotech Ltd; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• EXG110

Snippet

Sponsor: Guangzhou Jiayin Biotech Ltd | Conditions: Fabry Disease | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING